

**Supplementary Table 1. Clinicopathological profile of 272 lymphoma cases affecting the parotid glands and reported in literature from 2008 to 2024**

Study/Year	Cases per study	Sex	Age	Laterality	Diagnosis	Clinical presentation	Lymph node involvement	Symptoms/medical history	IHC/FISH/FC/PCR	Treatment	Outcome	Follow up (mo)	
Miyagi T et al., 2009	3	M	59	ND	ALCL	Homogeneous masses; ill-defined borders, enhancement (CT)	ND	No	(+): CD30, CD45RO (weakly) / (-): CD3, CD20, EMA, S100, keratin, HAM45	CHOP + RT	Alive	65	
		F	57	ND	ATLL		ND	No	(+): CD45RO	CHOP	Dead	8	
		F	88	ND	ATLL		Yes	No	(+): CD45RO	CHOP-like chemotherapy + RT	Dead	4	
Alvarez-Buylla Blanco M et al., 2010	8	F: 5 M:3	~74 (52-85)	Left: 87,5%	LGBL	Painless hard mass (more frequent) average size of 2,8cm	3 cases	SS	high grade B NHL: (+) CD20, CD79, CD3, ⅔ CD5, ⅓ CD43, ⅓ Bcl2	ND	R-CHOP, RT	Alive: 87.5%	At least 21
					HGBL			ND		R-CHOP, RT			
					HGBL			Waldenstrom disease		R-CHOP			
					HGBL			orbit and lip NHL	R-CHOP, RT				
					MALT			Hashimoto's thyroid	R-CHOP				
					MALT			ND	B MALT NHL: (+) CD20, CD79, ⅓ CD43	No			
					MALT			ND		No			
					FL			ND	ND	R-CHOP			
Nassie DI et al., 2010	13	M	54	Bilaterally: 1	Mixed B-cell lymphoma	painless mass	9 cases	Painless; Sistematic findings on PET-CT: 5	Diagnosis on the basis of histologic and immunohistologic consistent with lymphoma	Chlorambucil, RT	Alive	108	
		F	43		Marginal B-cell					CHOP, RT	Alive	120	
		M	46		LBCL					CHOP, RT	Alive	108	
		F	76	Unilaterally: 12	LBCL					COP	Dead	36	
		M	53		FL					ND	Alive	120	
		F	70		FL					Chlorambucil	Alive	84	

		M	75		T cell Rich B-cell Lymphoma					CHOP	Dead	108
		M	83		LBCL					R-CHOP	Alive	48
		M	76		BL					ND	Alive	36
		M	54		LGBL					R-CHOP + RT	Alive	24
		F	50		Mixed B-cell Lymphoma					ABVD + RT	Alive	36
		M	73		LBCL					CHOP + RT	Alive	12
		F	72		FL					No	Alive	12
Pollard RP et al., 2011	35	F	68	ND	MALT	PGS		SS, Arthralgia, arthritis	IHC was performed for at least CD3, CD5, CD20, CD79a, CD10, BCL6, and cytoplasmic immunoglobulins (kappa, lambda, IgM, IgG, and IgA).	Watchful waiting, Surgery	Alive	153
		F	77			ND		SS, Arthralgia, Fatigue	PCR: 21/35. All 21 cases revealed a dominant and reproducible monoclonal population of B cells in 1 or more framework PCR reactions.	Watchful waiting	Dead	109
		F	61			PGS		SS		Surgery	Alive	141
		M	33			PGS		SS, Arthritis, fatigue		Surgery + R-CP	Alive	124
		F	55			ND		SS, Arthralgia, arthritis		Watchful waiting	Alive	128
		F	28			PGS	Locally disseminated: 5	SS, Arthralgia, arthritis, RP		Surgery + RT	Alive	102
		F	64			PGS	Disseminated disease: 4	SS, Arthralgia, arthritis, fatigue		Watchful waiting	Alive	108
		F	36			PGS		SS, Arthralgia, fatigue, RP, fatigue		Rituximab, CYC	Alive	91
		M	62			ND		SS, Arthralgia, fatigue		Rituximab	Alive	78
		F	54			PGS		SS, Fatigue, vasculitis, pulmonary, hepatic and renal involvement		RT + CYC	Alive	153
		F	48			PGS		SS		Rituximab	Alive	141

		F	72			PGS		SS, Arthralgia, fatigue		Rituximab	Alive	75
		F	50			PGS		SS, Arthritis, fatigue, RP, vasculitis and esophageal involvement		Rituximab	Alive	66
		F	43			PGS		SS, Arthritis, fatigue, RP		Rituximab	Alive	70
		F	57			PGS		SS, Fatigue		Surgery + RT	Alive	100
		F	43			ND		SS, Fatigue		Rituximab	Alive	94
		F	76			ND		SS, Arthralgia, RP		Rituximab	Alive	83
		F	58			ND		SS, Fatigue		Rituximab	Alive	64
		M	36			PGS		SS, Fatigue		Rituximab	Alive	67
		F	57			PGS		SS, Fatigue		Watchful waiting	Alive	64
		F	67			PGS		SS, Fatigue, RP		Rituximab	Alive	57
		F	51			ND		SS, Arthralgia, fatigue		Rituximab	Alive	58
		F	57			PGS		SS, Fatigue		Surgery + RT + R-CP	Alive	85
		F	68			PGS		SS, Arthralgia		Watchful waiting	Alive	75
		F	41			PGS		SS, Arthralgia, fatigue		Watchful waiting	Alive	53
		F	65			PGS		SS, Fatigue		R-CP	Alive	49
		F	72			PGS		SS, Fatigue, RP		Watchful waiting	Alive	46
		F	64			PGS		SS, Fatigue, vasculitis, pulmonary and esophageal involvement, polyneuropathy		R-CP	Alive	50
		F	76			PGS		SS, Arthritis, RP		R-CP + RT	Alive	47
		F	65			PGS		SS, Arthralgia		Watchful waiting + RT	Alive	50
		F	60			ND		SS		R-CP	Alive	36

		F	85			PGS		SS, Fatigue		R-CP	Alive	28
		F	42			PGS		SS		Watchful waiting	Alive	28
		F	54			PGS		SS, Arthralgia		R-CP	Alive	26
		F	37			PGS		ND		Rituximab	Alive	16
Troch M et al., 2011	28	F	75	Left: 17	MALT	Unilateral or bilateral swelling: 26	ND	CREST Syndrome	All cases: light chain restriction and CD20+, CD5-, CD10-, cyclin D1-	Bortezomib	Dead	ND
	M	46	Right: 4	ND			SS	RT		Alive	10	
	F	31	Bilateral	ND			SS; Involvement of thymus	R-CHOP		Alive	ND	
	M	66	Bilateral	Yes			SS	Oxaliplatin		Dead	15	
	F	63	Left: 17 Right: 4	Yes			SHARP Syndrome; Lung involvement	R-CHOP		Alive	10	
	F	40	Bilateral	ND				RT		Alive	ND	
	M	65	Left: 17	ND			Orbit and kidney involvement	R-CHOP		Alive	ND	
	M	61	Right: 4	ND			SS	Wait and see		Alive	ND	
	F	47	Bilateral	ND			SS	RT		Alive	ND	
	F	36	Left: 17	ND			SS	Surgery		Alive	10	
	F	46	Right: 4	ND			Polymyalgia Rheumatica	RT		Alive	29	
	F	69	Bilateral	ND			ND	RT		Dead	18	
	F	42	Left: 17 Right: 4	ND			SS	RT		Alive	91	
	F	54		Yes			ND	Wait and see		Alive	ND	
	F	51		ND			SS	COP		Dead	51	
	F	54		ND			SS	R-CHOP		Alive	ND	
	M	31		ND			Hashimoto Thyroids	Surgery		Alive	18	
	F	50		ND			ND	Surgery		Alive	ND	
	F	35		ND			ND	Surgery		Alive	13	
	F	62		ND			ND	MCP		Alive	48	

		M	48				Yes	SS		MCP	Alive	ND
		F	39				ND	SS		Bortezomib	Alive	ND
		F	50				ND	SS		Surgery	Alive	ND
		M	35				Yes	ND		RT	Alive	27
		F	56				ND	ND		RT	Alive	55
		F	36	Bilateral			ND	SS		2-CdA	Alive	ND
		F	53	Bilateral			ND	ND		Wait and see	Alive	ND
		M	49	Left: 17 Right: 4			Yes	SS		RT	Alive	ND
Zenone T, 2012	2	F	56	Left	DLBCL	Enlarged left neck gland and large left neck mass;	ND	pSS	ND	chemotherapy + rituximab + localized radiation therapy	Dead	69
		F	42	Bilateral	MALT	Painful bilateral PGS	Yes	pSS, palpable purpura and hypothyroidism related to Hashimoto's thyroiditis  CT: heterogeneous hypertrophy	ND	Rituximab	Alive	26
Risselada AP et al., 2013	8	F	60		MALT	PGS	ND	pSS	ND	Surgery	Alive	73
		F	63		MALT	PGS	ND	pSS	ND	Wait-and-see	Alive	59
		F	59		MALT	PGS	ND	pSS	ND	Wait-and-see	Alive	30
		F	56		MALT	Small, hard node in parotid gland	ND	pSS	ND	Surgery	Alive	27
		M	59		MALT	PGS	Yes	pSS	ND	Chemotherapy + Rituximab	Alive	180
		F	52		MALT	PGS	ND	pSS, night sweats	ND	Chemotherapy + rituximab	Alive	9
		F	45		MALT	PGS	ND	pSS	ND	Rituximab	Alive	62
		F	54		MALT	PGS	ND	pSS	ND	Surgery	Alive	84

Wyss E et al., 2013	28	14F 14M	Mean age: 66 (28-93)	Left: 18 Right: 7 Bilateral: 2	FL	Progressing parotid mass: 27	6 cases	Pain: 7 Induration: 6 Dysesthesia: 5 Sicca symptoms: 5 Trismus: 1 SS: 4	ND	RT + COPM	Alive	39
					FL	Painless: 21			ND	Lateral parotidectomy + RT	Alive	114
					FL	Left hard palate ulceration: 1			ND	R-COP	Alive	30
					FL	No symptoms			ND	Lateral parotidectomy; watch and wait	Alive	8
					FL	-			ND	RT + Rituximab	Alive	21
					FL	-			ND	Rituximab	Dead	16
					FL	-			ND	Lateral parotidectomy; RT + Chlorambucil + prednisone + rituximab	Dead	63
					FL	-			ND	R-CHOP	Dead	4
					FL	-			ND	Total parotidectomy; RT + R-CHOP; R-Gemcitabine; Etoposide + ifosfamid (Holoxan); ESAP	Dead	127
					FL	-			ND	RT, CYC + Epirubicin + vinscritine (Oncovin) + Prednisone	Alive	210
					MALT	-			ND	Lateral parotidectomy; Patient refused further therapy	Alive	43
					MALT	-			ND	Lateral parotidectomy; RT	Alive	146
					MALT	-			ND	RT + CHOP + Rituximab	Dead***	13
					MALT	-			ND	RT	Alive	51
					MALT	-			ND	Lateral parotidectomy; Rituximab	Alive	30
MALT	-	ND	RT + Chlorambucil + Prednisone	Alive	75							
MALT	-	ND	Chorambucil + Prednisone	Dead	87							

					MALT	-			ND	Lateral parotidectomy; ND	Dead***	0
					MALT	-			ND	Total parotidectomy; No therapy, palliative with carcinoma	Dead***	24
					DLBCL	-			ND	Lateral parotidectomy; R-CHOP	Alive	17
					DLBCL	-			ND	Lateral parotidectomy; RT + R-CHOP	Alive	31
					DLBCL	-			ND	Chlorambucil + prednisone; Rituximab; CYC + Chlorambucil + Prednisone + Rituximab	Alive	72
					DLBCL	-			ND	CYC + Epirubicin + vincristine (Oncovin) + Prednisone	Dead***	37
					MCL	-			ND	Total parotidectomy; R-CHOP	Alive	23
					MCL	-			ND	R-COP	Dead	21
					Nodular lymphocyte-predominant Hodgkin lymphoma	-			ND	RT + CYC + vincristine (Oncovin) + Procarbazine (Natulan)	Alive	53
					Extrasosseous Plasmacytoma	-			ND	RT	Alive	59
					Chronic Lymphocytic Leukemia	-			ND	Total parotidectomy + Neck dissection; RT for carcinoma; watch and wait for CLL	Alive	22
Shum JW et al., 2014	3	F	53	Left	MALT	Growing mass	No	SS, Hashimoto thyroiditis	(+) CD20, CD19, CD22, CD23, CD52, Ki67~10 to 30%	RT	Alive	60
		M	53	Right	FL	PGS	Yes	No	(+) CD20, CD10, BCL2, Ki67~15 to 60%	R-CHOP + maintenance rituximab	Alive	24
		M	53	Right	FL	Mass in the preauricular region	No	No	(+) CD10, CD20, BCL2, BCL6	R-CHOP + RT	Alive	12

Yaprak N et al., 2015	8	2 M 6 F	mean age 46.6	4 right; 4 left	3 LGBL; 2 MALT; 2 HL; 1 HGBL	ND	ND	ND	ND	ChT/ChT+RT	ND	Range 7 to 108
Lieder A et al., 2017	19				1 HL; 9 FL; 7 marginal zone lymphoma; 2 NHL	84% Painless preauricular swelling	No	16% pain	ND	ChT/RT	2 Dead; 16 Alive	At least 72
Zhang Y et al., 2018	17	5 M 12 F	Mean age 47	11 right; 2 left; 4 bilateral	MALT	Diffused enlargement	ND	7 SS; 1 SS + Hashimoto thyroiditis	(+) CD20, CD43, CD79a, CK (-) CD3, lambda, kappa	Total/parcial excision, 4 surgery+ChT; 1 surgery+RT	17 Alive	Average: 53
Tesher MS et al., 2019	2	F	15	Left	MALT	PGS	ND	Fever, sore throat, headache, celiac disease, SS	(+) CD43	Rituximab, methylprednisolone, hydroxychloroquine	Alive	>36
		M	15	Right	MALT	PGS	ND	Left ankle pain, stiffness, dry mouth, dry eyes, SS	(+) CD20 (-) CD43, CD3	Parotidectomy; rituximab, bendamustine, hydroxychloroquine	Alive	24
Wang J et al., 2020	31	10 M 21 F	Mean age 64	27 Unilateral, 4 Bilateral	18 MALT, 7 DLBCL, 6 FL	Nodule or mass	9 cases	24 Painless, 5 Spontaneous pain, 1 Facial paralysis, 5 SS, 1 Rheumatoid arthritis	MALT (+) CD20, CD43, PAX-5   DLBCL (+) CD20, MUM-1, PAX-5   FL (+) CD20, CD10, Bcl6	6 Tumor resection, 3 surgery+RT, 14 surgery+ChT, 3 surgery+RT+ChT, 4 ChT, 1 RT+ChT	14 Dead, 17 Alive	Range 29 to 92
Mantsopoulos K et al., 2021	67	33 M 34 F	Mean age 61.4		6 HL, 21 MZL (12/21 MALT), 19 FL, 17 DLBCL, 2 MCL, 1 BL, 1 SLL	ND	10 cases	12 SS (patients with MALT), 3 with B symptoms	ND	13 Parotidectomy, 31 surgery+RT, 21 surgery+RT+ChT, 2 ND	ND	Range 20 to 158

F=female; M=male; SMG=submandibular gland; ALCL=Anaplastic Large Cell Lymphoma; ATLL=Adult T-cell Leukaemia/Lymphoma; MALT=mucosa-associated lymphoid tissue; FL=follicular lymphoma; LGBL=Low Grade B-cell Lymphoma; HGBL=High Grade B-cell Lymphoma; DLBCL=diffuse large B-cells lymphoma; FTCL=follicular T-cell lymphoma; ENKTL= Extranodal NK/T-cell lymphomas, MCL=mantle cell lymphoma; LBCL: Large B-cell Lymphoma; PTCL-NOS=peripheral T-cell lymphoma, not otherwise specified; HL=Hodgkin lymphoma; MZL=marginal zone lymphoma; BL=Burkitt lymphoma; SLL= Small-cell lymphocytic lymphoma; ND=not described; IHC=immunohistochemistry; FISH=fluorescence *in situ* hybridization; ISH=*in situ* hybridization; FC=flow cytometry; PCR=polymerase chain reaction; mo=months; RT=radiotherapy; ChT=chemotherapy; PGS=parotid gland swelling; SS=Sjogren Syndrome; RP=Raynaud's phenomenon; CYC=cyclophosphamide; R-CP=rituximab with cyclophosphamide and prednisone; Locally disseminated=lymphoma localized in 1 or more salivary glands (unilateral or bilateral) with 1 or more enlarged regional lymph nodes (> 1 cm); Disseminated disease=localization of lymphoma in 1 or more salivary glands (unilateral or bilateral) with 1 or more enlarged distant lymph nodes (> 1 cm), and/or bone marrow, spleen, liver, or other extranodal site than the salivary gland, or localization of lymphoma in multiple extranodal; MCP=mitoxantrone, chlorambucil, prednisolone; R-CNOP=rituximab, cyclophosphamide, mitoxantrone, vincristine, prednisolone; 2-CdA=2-chlorodeoxyadenosine; COPM=cyclophosphamide, vincristine (Oncovin), prednisone, rituximab (MabThera); ESAP=etoposide/ methylprednisolone (Solumedrol)/cytarabine (Ara C)/cisplatin